Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$20.17 - $23.93 $1.28 Million - $1.52 Million
-63,543 Reduced 13.74%
398,762 $9.46 Billion
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $8.9 Million - $11.2 Million
462,305 New
462,305 $11.1 Billion

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Cutter Capital Management, LP Portfolio

Follow Cutter Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutter Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutter Capital Management, LP with notifications on news.